Skip to main navigation
Skip to search
Skip to main content
The Hebrew University of Jerusalem Home
Approve / Request updates on publications
Home
Profiles
Research units
Research output
Prizes
Search by expertise, name or affiliation
The Role of Infliximab in Pediatric Ulcerative Colitis
Benjamin Koslowsky,
Dan Turner
Faculty of Medicine
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The Role of Infliximab in Pediatric Ulcerative Colitis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Crohn's Disease
100%
Pediatric Ulcerative Colitis
100%
Infliximab
100%
Autoimmunity
50%
Meta-analysis
50%
Prospective Cohort Study
50%
Lymphoma
50%
Pediatric Crohn's Disease
50%
Anti-tumor Necrosis Factor Antibody
50%
Anti-tumor Necrosis Factor (anti-TNF)
50%
Adult Crohn's Disease
50%
Immunomodulatory Therapy
50%
Anti-tumor Necrosis Factor Therapy
50%
Medicine and Dentistry
Pediatrics
100%
Ulcerative Colitis
100%
Crohn's Disease
100%
Infliximab
100%
Tumor Necrosis Factor
66%
Autoimmunity
33%
Prospective Cohort Study
33%
Meta-Analysis
33%
Immunomodulating Agent
33%
Tumor Necrosis Factor Antibody
33%
Pharmacology, Toxicology and Pharmaceutical Science
Crohn's Disease
100%
Ulcerative Colitis
100%
Infliximab
100%
Tumor Necrosis Factor
66%
Prospective Cohort Study
33%
Tumor Necrosis Factor Antibody
33%
Immunomodulating Agent
33%